Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: A randomized controlled trial

British Journal of Dermatology

Volumn 152, Issue 6, 2005, Pages 1296-1303

  Wolff, K ^a   Fleming, C ^b   Hanifin, J ^c   Papp, K ^d   Reitamo, S ^e   Rustinn, M ^f   Shear, N ^g   Silny, W ^h   Korman, N ⁱ   Marks, I ^j   Cherill, R ^j   Emady Azar, S ^j   Paul, Carle ^j  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Probity Medical   (Canada)

^e Hosp for Skin and Allergic Diseases   (Finland)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF TORONTO   (Canada)

^h POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Adults; Atopic dermatitis; Pimecrolimus; Randomized controlled trial

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOSPORIN; GAMMA INTERFERON; GLUCOSE; HISTAMINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; ARTICLE; ATOPIC DERMATITIS; BURNING SENSATION; CANCER RISK; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECZEMA; EMOTIONAL DISORDER; FATIGUE; FEMALE; FOLLOW UP; FURUNCLE; GASTROINTESTINAL DISEASE; HEADACHE; HERPES SIMPLEX; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMPETIGO; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; OUTCOMES RESEARCH; PHOTOTHERAPY; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; SHORT COURSE THERAPY; SINUS BRADYCARDIA; SKIN DISEASE; SKIN INFECTION; THORAX PAIN; TOOTH PAIN; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SAFETY; TACROLIMUS;

EID: 21644487962     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06674.x     Document Type: Article

References (24)

1. Hepburn D, Yohn JJ, Weston WL. Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994; 9:225-54.
2. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000; 39:1-14.
3. Bernard LA, Eichenfield LF. Topical immunomodulators for atopic dermatitis. Curr Opin Pediatr 2002; 14:414-18.
4. Sidbury R, Hanifin JM. Systemic therapy of atopic dermatitis. Clin Exp Dermatol 2000; 25:559-66.
5. Gallant C, Kenny P. Oral glucocorticoids and their complications. A review. J Am Acad Dermatol 1986; 14:161-77.
6. Akhavan A, Rudikoff D. The treatment of atopic dermatitis with systemic immunosuppressive agents. Clin Dermatol 2003; 21:225-40.
7. Berth-Jones J, Takwale A. Tan E et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol 2002; 147:324-30.
8. Zaki I, Emerson R, Allen BR. Treatment of severe atopic dermatitis in childhood with cyclosporin. Br J Dermatol 1996; 135 (Suppl. 48): 21-4.
9. Zachariae H. Renal toxicity of long-term cyclosporin. Scand J Rheumatol 1999; 28:65-8.
10. Grassberger M, Baumruker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141:264-73.
11. Hultsch T, Muller KD, Meingassner JG et al. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin- dependent manner. Arch Dermatol Res 1998; 290:501-7.
12. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5:643-55.
13. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119:876-87.
14. Griffiths C, Dubertret L, Gottlieb AB. Treatment with oral pimecrolimus significantly improves psoriasis with a clear dose-response effect. J Invest Dermatol 2003; 121: Abstract 0391.
15. Barbier N, Paul C, Luger T et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol 2004; 150:96-102.
16. Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46:495-504.
17. Sowden JM, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338:137-40.
18. Berth-Jones J, Graham-Brown RAC, Marks R et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol 1997; 136:76-81.
19. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol 2002; 43:247-54.
20. Granlund H, Erkko P, Sinisalo M et al. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132:106-12.
21. Krutmann J, Diepgen TL, Luger TA et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38:589-93.
22. Paul C, Lahfa M, Bachelez H et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147:518-22.
23. Sasaki K, Kojima M, Nakaizumi H et al. Early lens changes seen in patients with atopic dermatitis applying image analysis processing of Scheimpflug and specular microscopic images. Ophthalmologica 1998; 212:88-94.
24. Matsuo T, Saito H, Matsuo N. Cataract and aqueous flare levels in patients with atopic dermatitis. Am J Ophthalmol 1997; 124:36-9.